Tocilizumab in COVID-19: finding the optimal route and dose - Authors' reply
Lancet Rheumatol
.
2020 Dec;2(12):e739-e740.
doi: 10.1016/S2665-9913(20)30333-7.
Epub 2020 Sep 17.
Authors
Giovanni Guaraldi
1
2
,
Jovana Milic
2
3
,
Alessandro Cozzi-Lepri
4
,
Federico Pea
5
,
Cristina Mussini
1
2
Affiliations
1
Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena 41124, Italy.
2
Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy.
3
Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.
4
Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, UK.
5
Institute of Clinical Pharmacology, Azienda Ospedaliero-Universitaria Santa Maria Della Misericordia, University of Udine, Udine, Italy.
PMID:
32964210
PMCID:
PMC7498220
DOI:
10.1016/S2665-9913(20)30333-7
No abstract available